Mutation and expression analysis of the p73 gene in prostate cancer

Prostate

Volumn 39, Issue 2, 1999, Pages 94-100

  Yokomizo, Akira ^a   Mai, Ming ^a   Bostwick, David G ^a   Tindall, Donald J ^a   Qian, Junqi ^a   Cheng, Liang ^a   Jenkins, Robert B ^a   Smith, David I ^a   Liu, Wanguo ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allelic expression; Imprinting; Mutation; P73; Prostate cancer

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; DNA POLYMORPHISM; DNA SEQUENCE; GENE MUTATION; GENETIC ANALYSIS; GENOME IMPRINTING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS;

EID: 0033119215     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990501)39:2<94::AID-PROS3>3.0.CO;2-W     Document Type: Article

References (28)

1. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147: 92-101.
2. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996;56:3814-3822.
3. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996;48:971-979.
4. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-3373.
5. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
6. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 1996;27:573-580.
7. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819.
8. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 1997;389:191-194.
9. Takeda O, Homma C, Maseki N, Sakurai M, Kanda N, Schwab M, Nakamura Y, Kaneko Y. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 1994;10:30-39.
10. Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voute PA, Delattre O, Laureys G, Van Roy N, Speleman F. 1p36: every subband a suppressor? Eur J Cancer 1995;31:538-541.
11. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A. Mutation, allelotyping, and transcription analyes of the p73 gene in prostatic carcinoma. Cancer Res 1998;58:2076-2077.
12. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins R. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995;55: 4114-4119.
13. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
14. Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI, Liu W. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998;51:359-363.
15. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI, Liu W. Activation of p73 silent allele in lung cancer. Cancer Res 1998;58:2347-2349.
16. Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res 1998;26:1396-1400.
17. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith DI, Liu W. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17:475-479.
18. Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI, Liu W. Mutation analysis of the putative tumor suppressor PTEN/ MMAC1 in human ovarian cancer. Int J Oncol 1998;13:101-105.
19. Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick GD, Polychronakos C, Smith DI, Liu W. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene 1998;17: 1789-1741.
20. Nomoto S, Haruku N, Kondo M, Konishi H, Takahashi T, Takahashi T, Takahashi T. Search for mutations and examination of allele expression inbalance of p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998;58:1380-1383.
21. Tycko B. DNA methylation in genomic imprinting. Mutat Res 1997;386:131-140.
22. Watanabe D, Barlow DP. Random and imprinted monoallelic expression. Genes Cells 1996;1:795-802.
23. Svensson K, Mattsson R, James TC, Wentzel P, Pilartz M, MacLaughlin J, Miller SJ, Olsson T, Eriksson UJ, Ohlsson R. The paternal allele of the H19 gene is progressively silenced during early mouse development: the acetylation status of histones may be involved in the generation of variegated expression patterns. Development 1998;125:61-69.
24. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56:347-353.
25. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, Smith DI, Liu W. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999;in press.
26. Sinranski D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med 1996;47:285-301.
27. Goto K, Konomoto T, Hayashi K, Kinukawa N, Naito S, Kumazawa J, Tsuneyoshi M. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Mod Pathol 1997;10:428-437.
28. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994;151: 492-495.